Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
Docetaxel, trastuzumab, and pertuzumab, known as THP, is the preferred first-line treatment for HER2-positive advanced breast cancer, and the second-line drug of choice is trastuzumab emtansine. Most patients eventually develop resistance to systemic therapy. Trastuzumab deruxtecan, a novel HER2-tar...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2019-01-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=4;spage=556;epage=558;aulast=Dhanushkodi |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850189694052073472 |
|---|---|
| author | Manikandan Dhanushkodi |
| author_facet | Manikandan Dhanushkodi |
| author_sort | Manikandan Dhanushkodi |
| collection | DOAJ |
| description | Docetaxel, trastuzumab, and pertuzumab, known as THP, is the preferred first-line treatment for HER2-positive advanced breast cancer, and the second-line drug of choice is trastuzumab emtansine. Most patients eventually develop resistance to systemic therapy. Trastuzumab deruxtecan, a novel HER2-targeted antibody drug conjugate, has shown to be promising in this subset. It is a HER2-targeted antibody drug conjugate structurally composed of humanized anti-HER2 monoclonal antibody, cleavable tetra-peptide-based liker, and a potent payload (topoisomerase 1 inhibitor: Exatecan). A phase 2 trial of heavily pretreated advanced HER2-positive breast cancer (median of six lines of prior therapy) showed an overall response of 61% and a median progression-free survival of 16 months. In December 2019, the Food and Drug Administration announced accelerated approval of trastuzumab deruxtecan for HER2-positive advanced breast cancer patients who were prior exposed to two or more lines of anti-HER2 therapy in a metastatic setting. |
| format | Article |
| id | doaj-art-dd71271e44664a73b196d6c4590b81e3 |
| institution | OA Journals |
| issn | 0971-5851 0975-2129 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | Indian Journal of Medical and Paediatric Oncology |
| spelling | doaj-art-dd71271e44664a73b196d6c4590b81e32025-08-20T02:15:33ZengThieme Medical and Scientific Publishers Pvt. Ltd.Indian Journal of Medical and Paediatric Oncology0971-58510975-21292019-01-0140455655810.4103/ijmpo.ijmpo_264_19Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancerManikandan DhanushkodiDocetaxel, trastuzumab, and pertuzumab, known as THP, is the preferred first-line treatment for HER2-positive advanced breast cancer, and the second-line drug of choice is trastuzumab emtansine. Most patients eventually develop resistance to systemic therapy. Trastuzumab deruxtecan, a novel HER2-targeted antibody drug conjugate, has shown to be promising in this subset. It is a HER2-targeted antibody drug conjugate structurally composed of humanized anti-HER2 monoclonal antibody, cleavable tetra-peptide-based liker, and a potent payload (topoisomerase 1 inhibitor: Exatecan). A phase 2 trial of heavily pretreated advanced HER2-positive breast cancer (median of six lines of prior therapy) showed an overall response of 61% and a median progression-free survival of 16 months. In December 2019, the Food and Drug Administration announced accelerated approval of trastuzumab deruxtecan for HER2-positive advanced breast cancer patients who were prior exposed to two or more lines of anti-HER2 therapy in a metastatic setting.http://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=4;spage=556;epage=558;aulast=Dhanushkodiadvanced breast cancerher2 positivetrastuzumab deruxtecan |
| spellingShingle | Manikandan Dhanushkodi Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer Indian Journal of Medical and Paediatric Oncology advanced breast cancer her2 positive trastuzumab deruxtecan |
| title | Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer |
| title_full | Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer |
| title_fullStr | Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer |
| title_full_unstemmed | Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer |
| title_short | Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer |
| title_sort | trastuzumab deruxtecan a quantum leap in her2 positive breast cancer |
| topic | advanced breast cancer her2 positive trastuzumab deruxtecan |
| url | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=4;spage=556;epage=558;aulast=Dhanushkodi |
| work_keys_str_mv | AT manikandandhanushkodi trastuzumabderuxtecanaquantumleapinher2positivebreastcancer |